Key Points
- Director George Jenkins sold 13,352 Palvella Therapeutics shares at an average price of $151.96, generating approximately $2.03 million. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, leaving him with 161,893 shares.
- Palvella’s stock opened at $151.22, near its 52-week high of $161.38, while the company reported a quarterly loss of $1.52 per share—worse than analysts’ expected loss of $1.17.
- Despite the earnings miss, analysts maintain a largely positive outlook, with an average rating of “Buy” and an average price target of $209.14. Institutional investors own approximately 40.11% of the company.
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) Director George Jenkins sold 1,777 shares of the firm's stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $150.14, for a total transaction of $266,798.78. Following the sale, the director directly owned 160,116 shares of the company's stock, valued at $24,039,816.24. This trade represents a 1.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Palvella Therapeutics Trading Down 0.3%
PVLA stock opened at $151.22 on Wednesday. The stock has a market capitalization of $2.18 billion, a PE ratio of -31.31 and a beta of -0.25. Palvella Therapeutics, Inc. has a 12-month low of $54.28 and a 12-month high of $161.38. The stock's 50 day simple moving average is $149.13 and its 200 day simple moving average is $132.62.
Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.35). On average, research analysts predict that Palvella Therapeutics, Inc. will post -6.36 earnings per share for the current year.
Institutional Trading of Palvella Therapeutics
A number of hedge funds have recently bought and sold shares of PVLA. Arizona State Retirement System lifted its holdings in Palvella Therapeutics by 30.9% in the second quarter. Arizona State Retirement System now owns 2,765 shares of the company's stock valued at $423,000 after acquiring an additional 652 shares during the period. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Palvella Therapeutics during the 2nd quarter valued at about $35,000. Penn Capital Management Company LLC purchased a new stake in shares of Palvella Therapeutics during the 2nd quarter valued at about $841,000. Hsbc Holdings PLC purchased a new stake in shares of Palvella Therapeutics during the 2nd quarter valued at about $7,641,000. Finally, Wellington Management Group LLP lifted its stake in shares of Palvella Therapeutics by 4.6% in the 2nd quarter. Wellington Management Group LLP now owns 35,594 shares of the company's stock worth $5,439,000 after purchasing an additional 1,554 shares during the period. Hedge funds and other institutional investors own 40.11% of the company's stock.
Analyst Ratings Changes
Several equities research analysts recently commented on the company. Stephens reaffirmed an "overweight" rating and set a $220.00 price objective on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Truist Financial set a $207.00 target price on Palvella Therapeutics in a research report on Wednesday, August 5th. Canaccord Genuity Group set a $232.00 target price on shares of Palvella Therapeutics in a research note on Wednesday, August 5th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Palvella Therapeutics in a report on Monday, June 29th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $270.00 price target on shares of Palvella Therapeutics in a report on Wednesday, July 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $209.14.
Read Our Latest Analysis on PVLA
About Palvella Therapeutics
(
Get Free Report)
Palvella Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with rare genetic and dermatologic diseases. The company uses its proprietary QTORIN platform to formulate and deliver medicines locally to affected tissues, with the goal of improving treatment effectiveness while limiting systemic exposure.
Palvella's lead program is QTORIN 3.9% rapamycin, an investigational topical gel being developed for microcystic lymphatic malformations, rare lesions caused by abnormalities in the lymphatic system.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
